暨南大学生命科学技术学院导师教师师资介绍简介-陈良

删除或更新信息，请邮件至freekaoyan#163.com(#换成@)

本站小编 Free考研考试/2021-05-22

个人信息

姓名：陈良
部门：生命科学技术学院
直属机构：生化与分子生物学系（生命与健康工程研究院）
性别：男
--> 职务：实验室主任
职称：研究员
学位：博士
毕业院校：中国科学院上海生物化学与细胞生物学研究所
联系电话：
电子邮箱： chenliang@email.jnu.edu.cn
办公地址：暨南大学第二理工楼6楼643办公室
通讯地址：暨南大学第二理工楼6楼643办公室
邮编： 510632
传真：
荣誉奖励：珠江学者

联系方式

130 5121 182
020-8522 2875

个人简介

陈良博士，973首席科学家，自2010年回国一直致力于肺癌的研究。在肺癌的治疗和肺癌的早期诊断做出了突出的贡献。以第一作者和通讯作者的身份在Nature, Nature Medicine等SCI杂志上发表14篇文章。参与并以共同作者发表了18篇SCI文章。曾作为首席科学家主持973项目，并参与子课题的研究，国家自然科学基金面上项目3项，在研国家自然科学基金委应急管理项目1项，国家重点研发计划“精准医学”专项1项，以及2017年度省科技发展专项资金项目1项。是《Oncotarget》、《Scientific Reports》和《Acta Biochimica et Biophysica Sinica: Oxford Journals》的审稿人，《International Journal of Translational Research》和《The Open Biomarkers Journal》的编辑。还兼任北京生物工程协会第四届理事。
本人于2016年10月进入暨南大学工作，组建了肺癌精准医疗实验室，并开展肺癌的早期诊断、肺癌的癌变机理、及肺癌的治疗研究。肺癌的早期诊断：实验室利用病人的临床样本、转基因肺癌小鼠模型、及肺癌细胞模型鉴定病人远端体液中适合用于肺癌早期诊断的蛋白标志物。通过蛋白组学、分子生物学、及细胞生物学等手段鉴定的对象主要集中在由肺癌细胞分泌，对肺癌细胞生存起着关键作用的、并高浓度出现在病人的尿液中的蛋白。肺癌的癌变机理：目前实验室主要通过全基因组规模的筛选，鉴定肺癌的抑癌基因，并解析这些新型的肺癌抑癌基因的生物学功能机理。基于解析的抑癌基因的信号传导机制，研究相应肺癌的治疗策略。肺癌的治疗研究。实验室正在开展药物的研究。主要集中在免疫检查点的小分子抑制剂的开发及生物大分子的开发。利用细胞模型及免疫功能正常的转基因肺癌小鼠模型测试这些药物治疗肺癌的能力。并解析药物起功能的分子机制。
本人致力于建立既成药物的高通量筛选平台，转基因小鼠平台，小动物病理诊断平台。

学习经历

2002:PhD, Shanghai Institute of Biochemistry and Cell Biology, CAS, China
1997:BSc, Hangzhou University, China

工作经历

2016 - Present: Professor, Jinan University, China
2010 – 2016: Professor, National Institute of Biological Sciences, Beijing
2005 – 2010: Postdoc - Dana-Farber Cancer Institute, Harvard Medical School, USA
2002 – 2005: Yale School of Medicine, USA

研究方向

开展肺癌的早期诊断、肺癌的癌变机理及肺癌的治疗研究。

主要论文

1.Fan Z#, Tian Y#, Chen Z, Liu L, Zhou Q, He J, Coleman J, Dong C, Li N, Huang J, Xu C, Zhang Z, Gao S, Zhou P, Ding K, Chen L. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors, EMBO Mol Med. 2020 May 11:e11571. doi: 10.15252/emmm.
2.Li B, Liang J, Lu F, Zeng G, Zhang J, Ma Y, Liu P, Wang Q, Zhou Q, Chen L, Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Molecules. 2020 Apr 6;25(7). pii: E1680. doi: 10.3390/molecules**.
3.Lu F, Zhou Q, Liu L, Zeng G, Ci W, Liu W, Zhang G, Zhang Z, Wang P, Zhang A, Gao Y, Yu L, He Q, Chen L., A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients, Theranostics, 2020; 10(2): 484-497. doi: 10.7150/thno.38060
4.GaoL., Hu Y., Tian Y., Fan Z., Wang K., Li H., Zhou Q., Zeng G., Hu X., Yu L., Zhou Sh., Tong X., Huang H., Chen H., Liu Q., Liu W., Zhang G., Zeng M., Zhou G., He Q., Ji H., Chen L., Lung Cancer Deficient in the Tumor Suppressor GATA4 are Sensitive to TGFBR1 Inhibition，Nature Communications, 2019 Apr 10;10(1):1665. doi: 10.1038/s41467-019-09295-7
5.Wu Q, Tian Y, Zhang J, Tong X, Huang H, Li S, Zhao H, Tang Y, Yuan C, Wang K, Fang Z, Gao L, Hu X, Li F, Qin Z, Yao S, Chen T, Chen H, Zhang G, Liu W, Sun Y, Chen L, Wong KK, Ge K, Chen L#, Ji H. In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3978-E3986. (# co-corresponding)
6.Li S, Jiang Q, Liu S, Zhang Y, Tian Y, Song C, Wang J, Zou Y, Anderson G, Han J, Chang Y, Liu Y, Zhang C, Chen L, Zhou G, Nie G, Yan H, Ding B & Zhao Y. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat Biotechnol.2018 Feb 12. doi: 10.1038/nbt.4071
7.Gao R, Xiu W, Zhang L, Zang R, Yang L, Wang C, Wang M, Wang M, Yi L, Tang Y, Gao Y, Wang H, Xi J, Liu W, Wang Y, Wen X, Yu Y, Zhang Y, Chen L#, Chen J#, Gao S#.Direct induction of neural progenitor cells transiently passes through a partially reprogrammed state. Biomaterials. 2016 Dec 10;119:53-67. doi: 10.1016/j.biomaterials (# co-corresponding)
8.Mikse OR, Tchaicha JH, Akbay EA, Chen L, Bronson RT, Hammerman PS, Wong KK., The impact of the MYB-NFIB fusion protooncogene in vivo. Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9426.
9.Yang H, Zhang W, Lu S, Lu G, Zhang H, Zhuang Y, Wang Y, Dong M, Zhang Y, Zhou X, Wang P, Yu L, Wang F, and Chen L., Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis. Acta Biochim Biophys Sin, 2016 May;48(5):468-73. doi: 10.1093/abbs/gmw003
10.Zhang H, Zhan C, Ke J, Xue Z, Zhang A, Xu K, Shen Z, Yu L, Chen L., EGFR Kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment, Oncotarget, 2015 Dec 8. DOI: 10.18632/oncotarget.6491
11.Xu N., Fang W., Mu L., Tang Y., Gao L., Ren S., Cao D., Zhou L., Zhang A., Liu D., Zhou C., Wong K., Yu L., Zhang L., Chen L., Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2015 Dec 4. doi: 10.18632/oncotarget.6461
12.Gao L., Jiang Y., Mu L., Liu Y., Wang F, Wang P., Zhang A., Tang N., Chen T., Luo M., Yu L., Gao S., Chen L. Efficient Generation of Mice with Consistent Transgene Expression by FEEST, Sci Rep. 2015, 5:16284; doi: 10.1038/srep16284
13.Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q, Zeng MS., Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis.2015 Oct 15;6:e1920
14.Hu Z, Hu Y, Liu X, Xi R, Zhang A, Liu D, Xie Q and Chen L, Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor, Oncotaget,2015 Oct 13;6(31):31628-39. doi: 10.18632/oncotarget.5221
15.Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan X, Zhao P, Wang J, Wang C, Weisberg E, Gray N, Yun C, Liu J, Chen L#, Liu Q#. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.Oncotarget, 2015 Oct 13;6(31):31313-22. doi: 10.18632/oncotarget.5182 (# co-corresponding)
16.Zhang H, Cao J, Li L, Liu Y, Zhao H, Li N, Li B, Zhang A, Huang H, Chen S, Dong M, Yu L, Zhang J, Chen L.,Identification of urine protein biomarkers with the potential for early detection of lung cancer. Sci Rep.2015 Jul 2;5:11805. doi: 10.1038/srep11805.
17.Hu Z, Wan X, Hao R, Zhang H, Li L, Li L, Xie Q, Wang P, Gao Y, Chen S, Wei M, Luan Z, Zhang A, Huang N,Chen L., Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS One. 2015 Apr 8;10(4):e**.
18.Zhu G, Fan Z, Ding M, Zhang H, Mu L, Ding Y, Zhang Y, Jia B, Chen L,Chang Z, Wu W, An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene.2015 Mar 9. doi: 10.1038/onc.2015.45
19.Ding X, Yang Y, Han B, Du C, Xu N, Huang H, Cai T, Zhang A, Han ZG, Zhou W, Chen L.Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One.2014 May 5;9(5):e95307
20.Chen Z, Akbay EA, Mikse OR, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L,Reibel J, Janne PA, Engelman JA, Sharpless NE, Kung AL, Shapiro GI, Wong KK. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 2014 Mar 1;20(5):1204-11.
21.Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich HE, Johnson BE, Eck MJ, Janne PA, Wong KK, Meyerson M. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res.2013 Nov 15;73(22):6770-9
22.Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L,Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. Epub 2012 Jul 17.
23.Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S,Chen L, Collett K, Bachmann I, Wong K-K, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. Epub 2012 May 15
24.Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashgarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol2011 Jan 186 (1), 527-538.
25.M-C Liang, J Ma, L Chen, P Kozlowski, W Qin, D Li, J Goto, T Shimamura1, DN Hayes, M Meyerson, DJ Kwiatkowski and K-K Wong, TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity, Oncogene, 2010 Mar 18;29(11):1588-97
26.Zhou W(*), Ercan D(*), Chen L(*), Yun C(*), Li D, Capelletti M, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck M, Gray NS and J?nne PA., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature,2009 Dec 24;462(7276):1070-4, (*equal contribution)
27.Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK., HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy, Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.
28.Engelman JA(*), Chen L(*), Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008 Dec;14(12):1351-6. (* equal contribution)
29.Girnun GD (*),Chen L(*), Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK., Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008 Oct 15;14(20):6478-86. (* equal contribution)
30.Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK., Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis. 2008 Apr;29(4):747-53.
31.Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, J?nne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK., LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16;448(7155):807-10.
32.Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, J?nne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272, Cancer Cell. 2007 Jul;12(1):81-93
33.Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, J?nne PA, Johnson BE, Chin L, Wong KK., Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15;67(10):4933-9.
34.Chen L(*), He W(*), Kim ST, Tao J, Gao Y, Chi H, Intlekofer AM, Harvey B, Reiner SL, Yin Z, Flavell RA, Craft J.. Epigenetic and Transcriptional Programs Lead to Default IFN-gamma Production by gamma/delta T Cells. 2007 Mar; J Immunol. 178(5):2730-2736. (* equal contribution)
35.Tao J, Gao Y, Li MO, He W, Chen L, Harvev B, Davis RJ, Flavell RA, Yin Z. JNK2 negatively regulates CD8(+) T cell effector function and anti-tumor immune response. Eur J Immunol. 2007 Mar;37(3):818-829.
36.Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, J?nne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK., The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun;9(6):485-95.
37.Wisnewski AV, Stowe MH, Cartier A, Liu Q, Liu J, Chen L, Redlich CA., Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol. 2004 Jun;113(6):1178-1184.
38.Wisnewski AV, Herrick CA, Liu Q, Chen L, Bottomly K, Redlich CA. Human gamma/delta T-cell proliferation and IFN-gamma production induced by hexamethylene diisocyanate. J Allergy Clin Immunol. 2003 Sep;112(3):538-546.
39.Chen L, Li G, Tang L, Wang J, Ge XR, The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv. Cell Res.2002 Mar;12(1):47-54.

主要著作

承担课题

--【在研】
国家自然科学基金委员会面上项目，**（2020.01 – 2023.12），非小细胞肺癌干性抑癌基因的系统筛选及机理解析，项目负责人，55万元。
国家自然科学基金委员会面上项目**（2017.01 – 2020.12），PD-1小分子抑制剂的开发与其作用分子机理和肺癌治疗的研究，项目负责人，52万元。
国家重点研发计划“精准医学”专项—肺癌诊疗规范及应用方案的精准化研究2016YFC**（2016.07 – 2020.06），670.00万元。课题骨干，50万元。
广东省科技计划重点项目，晚期肺癌的精准医学临床应用研究2017B（2017.01 – 2020.12），300万。课题骨干，60万元。
广东省教育厅珠江学者特聘教授基金（2018.10 – 2021.9），200万元。
广州市科技计划项目民生科技攻关计划生物医药与健康专题，肺癌癌变机理及肺癌精准治疗方案的研究4（2018.04 – 2020.03），项目负责人，100万元。
暨南大学高层次人才研究启动项目**（2017 – 2021），项目负责人，1,100万元。
暨南大学中央高校基本科研业务费（理工医）项目，新型PD-1小分子抑制剂的开发**（2019.01 – 2021.12），50万元。
--【已结题】
科技部973重大科学专项2011CB812401（2011.04 – 2013.12），抗癌小分子化合物的筛选和治疗效果的评价。课题负责人，1202万元。
科技部973重大科学专项2011CB812400（2011.06 – 2013.12）癌症中激酶机理的研究和在全新靶向药物分子开发中的应用，首席科学家，3408万元。
国家自然科学基金委员会面上项目**（2015.01 – 2018.12），中国肝癌和肺癌病人中HER2突变体对其蛋白功能影响及对靶向药物的反应机理的研究，项目负责人，72万元。
国家自然科学基金委员会面上项目**（2015.01 – 2018.12），多环芳烃受体介导的肺癌EGFR-TKI耐药新机制实验研究，项目参与人，75万元。

发明专利

1、陈良，高磊。一种评价EML-ALK抑制剂对肺癌治疗效果的方法，中国，1.3
2、陈良，范真真。吩噻嗪类或其类似结构的化合物在制药中的新应用，中国，8.5
3、王长利，张彬，陈良，马宇辰，陈智鹏，刘翠翠，岳东升，沙永生，田鹏飞，张华，潘家强，范真真。肺癌尿液分子标志物MDH2在用于肺癌辅助诊断方面的应用，中国，1.9
4、陈良，陈智鹏。一种治疗肺癌的药物，中国，3

讲授课程

《肿瘤分子生物学》

荣誉奖励

珠江学者

社会职务

2017.09–至今Editor, The Open Biomarkers Journal
2017.03–至今Editor, International Journal of Translational Research
2017–至今科技部国家重大科学研究计划评审专家
2014–至今北京市第四届生物工程协会理事
2012–至今农业部转基因重大专项评审专家
2018–至今广东省创新创业团队项目评审专家
2018–至今科技部干细胞及转化研究重大专项专项评审专家
2019–至今广东省自然基金杰出青年项目评审专家